Capricor Therapeutics Inc (NASDAQ: CAPR)’s stock price has plunge by 3.68relation to previous closing price of 17.14. Nevertheless, the company has seen a -17.92% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-11 that -Data Supports Deramiocel’s Sustained Efficacy and Safety in Treating DMD- -Improvements Seen in Multiple Cardiac and Skeletal Endpoints Demonstrating Stabilization of Cardiac and Skeletal Muscle Function Over 3 Years of Treatment- -Company on Track to Fully Submit Biologics License Application (BLA) by End of 2024- SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive 3-year safety and efficacy results from its ongoing HOPE-2 open label extension (OLE) study for its lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD). The data was highlighted in a late-breaking poster presentation at the 29th Annual Congress of the World Muscle Society (WMS), October 8-12, 2024 in Prague, Czechia.
Is It Worth Investing in Capricor Therapeutics Inc (NASDAQ: CAPR) Right Now?
Company’s 36-month beta value is 4.05.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CAPR is 27.08M, and currently, short sellers hold a 19.35% ratio of that floaft. The average trading volume of CAPR on October 14, 2024 was 2.50M shares.
CAPR’s Market Performance
CAPR stock saw an increase of -17.92% in the past week, with a monthly gain of 325.12% and a quarterly increase of 281.33%. The volatility ratio for the week is 19.02%, and the volatility levels for the last 30 days are 19.06% for Capricor Therapeutics Inc (CAPR). The simple moving average for the past 20 days is 45.00% for CAPR’s stock, with a 212.42% simple moving average for the past 200 days.
Analysts’ Opinion of CAPR
Many brokerage firms have already submitted their reports for CAPR stocks, with Oppenheimer repeating the rating for CAPR by listing it as a “Outperform.” The predicted price for CAPR in the upcoming period, according to Oppenheimer is $14 based on the research report published on May 17, 2024 of the current year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see CAPR reach a price target of $8. The rating they have provided for CAPR stocks is “Overweight” according to the report published on January 05th, 2024.
Ladenburg Thalmann gave a rating of “Buy” to CAPR, setting the target price at $15 in the report published on October 26th of the previous year.
CAPR Trading at 139.25% from the 50-Day Moving Average
After a stumble in the market that brought CAPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.15% of loss for the given period.
Volatility was left at 19.06%, however, over the last 30 days, the volatility rate increased by 19.02%, as shares surge +287.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +354.48% upper at present.
During the last 5 trading sessions, CAPR fell by -17.92%, which changed the moving average for the period of 200-days by +270.21% in comparison to the 20-day moving average, which settled at $12.26. In addition, Capricor Therapeutics Inc saw 263.39% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CAPR starting from Nippon Shinyaku Co Ltd, who purchase 2,798,507 shares at the price of $5.36 back on Sep 20 ’24. After this action, Nippon Shinyaku Co Ltd now owns 7,090,351 shares of Capricor Therapeutics Inc, valued at $14,999,998 using the latest closing price.
Stock Fundamentals for CAPR
Current profitability levels for the company are sitting at:
- -1.1 for the present operating margin
- 0.95 for the gross margin
The net margin for Capricor Therapeutics Inc stands at -1.03. The total capital return value is set at -1.87. Equity return is now at value -392.69, with -66.31 for asset returns.
Based on Capricor Therapeutics Inc (CAPR), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -8.14. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is 0.07.
Currently, EBITDA for the company is -23.01 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 21.09. The receivables turnover for the company is 73.39for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.
Conclusion
In a nutshell, Capricor Therapeutics Inc (CAPR) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
